Related Experiment Video

Updated: Aug 23, 2025

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
10:28

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

8.4K

Inhibition of human glioblastoma multiforme cells by 10,11-dehydrocurvularin through the MMP-2 and PI3K/AKT signaling

Hao Yan1, Zhenhao Fu2, Pingxin Lin1

  • 1National Engineering Research Center for Cereal Fermentation and Food Biomanufacturing, Jiangnan University, Wuxi, 214122, China.

European Journal of Pharmacology
|October 28, 2022
PubMed

Insights

10,11-dehydrocurvularin (DCV) inhibits glioblastoma cell growth, migration, and invasion, and promotes apoptosis. This compound shows potential as a novel chemotherapeutic agent for glioblastoma treatment.

Area of Science:

  • Neuro-oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis.
  • Current treatments face challenges due to tumor resistance and recurrence.
  • Novel therapeutic strategies are urgently needed for glioblastoma treatment.

Purpose of the Study:

  • To investigate the anti-glioma activity of 10,11-dehydrocurvularin (DCV).
  • To explore the underlying mechanisms of DCV's effect on glioblastoma cells.

Main Methods:

  • Assessed DCV's impact on glioblastoma cell lines (U251, U87) versus normal human epidermal cells (HEB).
  • Evaluated effects on cell proliferation, colony formation, migration, invasion, and apoptosis.
  • Analyzed DCV's influence on the PI3K/AKT pathway, including AKT phosphorylation and MMP2 levels.

Main Results:

  • DCV significantly inhibited glioblastoma cell proliferation, colony formation, migration, and invasion.
  • DCV treatment induced apoptosis in glioblastoma cells.
  • DCV suppressed AKT phosphorylation and reduced matrix metalloproteinase-2 (MMP2) levels, a downstream target of the PI3K/AKT pathway.

Conclusions:

  • 10,11-dehydrocurvularin (DCV) exhibits potent anti-glioblastoma properties.
  • DCV's mechanism involves the inhibition of the PI3K/AKT signaling pathway.
  • DCV represents a promising candidate for the development of new glioblastoma chemotherapeutic drugs.
Keywords:
10,11-dehydrocurvularinChemotherapyGlioblastoma multiformeMMP-2PI3K/AKT

More Related Videos

Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion09:23

Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion

Published on: October 20, 2016

14.1K
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

15.9K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K